Cho‐Ming Loi

2.5k total citations
44 papers, 1.7k citations indexed

About

Cho‐Ming Loi is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, Cho‐Ming Loi has authored 44 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Pharmacology and 14 papers in Molecular Biology. Recurrent topics in Cho‐Ming Loi's work include Pharmacogenetics and Drug Metabolism (16 papers), Drug Transport and Resistance Mechanisms (12 papers) and Advanced Breast Cancer Therapies (6 papers). Cho‐Ming Loi is often cited by papers focused on Pharmacogenetics and Drug Metabolism (16 papers), Drug Transport and Resistance Mechanisms (12 papers) and Advanced Breast Cancer Therapies (6 papers). Cho‐Ming Loi collaborates with scholars based in United States, Switzerland and United Kingdom. Cho‐Ming Loi's co-authors include Susan Hurst, Barry J. Cusack, Jeffrey R. Koup, Robert E. Vestal, Artemios B. Vassos, Edward J. Randinitis, Ayman El‐Kattan, Joanne Brodfuehrer, Deepak Dalvie and Michael J. Graziano and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Cho‐Ming Loi

44 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cho‐Ming Loi United States 23 691 615 611 153 145 44 1.7k
J. Greg Slatter United States 21 762 1.1× 666 1.1× 540 0.9× 166 1.1× 154 1.1× 50 1.9k
David R. Jones United States 19 576 0.8× 765 1.2× 979 1.6× 311 2.0× 177 1.2× 35 2.3k
Geert Mannens Belgium 25 550 0.8× 472 0.8× 749 1.2× 289 1.9× 330 2.3× 59 2.1k
Hidetaka Kamimura Japan 24 423 0.6× 676 1.1× 651 1.1× 255 1.7× 231 1.6× 98 1.6k
Satoru Asahi Japan 16 382 0.6× 449 0.7× 455 0.7× 188 1.2× 91 0.6× 52 1.3k
Adrian J. Fretland United States 22 1.1k 1.7× 376 0.6× 437 0.7× 99 0.6× 123 0.8× 52 2.1k
Heidi J. Einolf United States 25 538 0.8× 499 0.8× 776 1.3× 175 1.1× 139 1.0× 39 1.6k
S. Cholerton United Kingdom 24 716 1.0× 370 0.6× 937 1.5× 107 0.7× 148 1.0× 40 2.1k
Mats Hidestrand United States 26 549 0.8× 439 0.7× 876 1.4× 229 1.5× 183 1.3× 40 1.8k
Alvin Gomez Sweden 15 660 1.0× 489 0.8× 783 1.3× 158 1.0× 195 1.3× 18 1.7k

Countries citing papers authored by Cho‐Ming Loi

Since Specialization
Citations

This map shows the geographic impact of Cho‐Ming Loi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cho‐Ming Loi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cho‐Ming Loi more than expected).

Fields of papers citing papers by Cho‐Ming Loi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cho‐Ming Loi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cho‐Ming Loi. The network helps show where Cho‐Ming Loi may publish in the future.

Co-authorship network of co-authors of Cho‐Ming Loi

This figure shows the co-authorship network connecting the top 25 collaborators of Cho‐Ming Loi. A scholar is included among the top collaborators of Cho‐Ming Loi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cho‐Ming Loi. Cho‐Ming Loi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Loi, Cho‐Ming, Dennis A. Smith, & Deepak Dalvie. (2013). Which Metabolites Circulate?. Drug Metabolism and Disposition. 41(5). 933–951. 29 indexed citations
2.
Heyen, Jonathan R., Wenyue Hu, Joseph Jamieson, et al.. (2013). Cardiovascular differentiation of imatinib and bosutinib in the rat. International Journal of Hematology. 98(5). 597–607. 3 indexed citations
3.
Bello, Carlo L., et al.. (2013). A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers. Cancer Chemotherapy and Pharmacology. 72(2). 379–385. 35 indexed citations
4.
Kraynov, Eugenia, Steven W. Martin, Susan Hurst, et al.. (2011). How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential. Drug Metabolism and Disposition. 39(10). 1779–1783. 14 indexed citations
5.
Murray, Brion W., Chuangxing Guo, Joseph Piraino, et al.. (2010). Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proceedings of the National Academy of Sciences. 107(20). 9446–9451. 253 indexed citations
6.
Dalvie, Deepak, Chenghong Zhang, Wei‐Chao Chen, et al.. (2009). Cross-Species Comparison of the Metabolism and Excretion of Zoniporide: Contribution of Aldehyde Oxidase to Interspecies Differences. Drug Metabolism and Disposition. 38(4). 641–654. 60 indexed citations
7.
8.
Hurst, Susan, Cho‐Ming Loi, Joanne Brodfuehrer, & Ayman El‐Kattan. (2007). Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opinion on Drug Metabolism & Toxicology. 3(4). 469–489. 74 indexed citations
9.
Koup, Jeffrey R., Jing Liu, Cho‐Ming Loi, et al.. (2004). PK/PD modeling of biomarker (p-ERK) response and tumor growth to PD 0325901 in a human tumor xenograft mouse model. Cancer Research. 64. 1248–1248. 2 indexed citations
10.
Sebolt–Leopold, Judith S., Ronald L. Merriman, Charles A. Omer, et al.. (2004). The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential. Cancer Research. 64. 925–925. 15 indexed citations
11.
Lin, Yvonne S., G. Lockwood, Martin A. Graham, et al.. (2001). In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 11(9). 781–791. 101 indexed citations
12.
Loi, Cho‐Ming, et al.. (1999). Effect of Troglitazone on the Pharmacokinetics of an Oral Contraceptive Agent. The Journal of Clinical Pharmacology. 39(4). 410–417. 28 indexed citations
13.
Loi, Cho‐Ming, Malcolm A. Young, Edward J. Randinitis, Artemios B. Vassos, & Jeffrey R. Koup. (1999). Clinical Pharmacokinetics of Troglitazone. Clinical Pharmacokinetics. 37(2). 91–104. 103 indexed citations
14.
Koup, Jeffrey R., Gail D. Anderson, & Cho‐Ming Loi. (1998). Effect of Troglitazone on Urinary Excretion of 6β‐Hydroxycortisol. The Journal of Clinical Pharmacology. 38(9). 815–818. 27 indexed citations
15.
Loi, Cho‐Ming, Christine Alvey, Edward J. Randinitis, et al.. (1997). Meta‐Analysis of Steady‐State Pharmacokinetics of Troglitazone and Its Metabolites. The Journal of Clinical Pharmacology. 37(11). 1038–1047. 22 indexed citations
16.
Loi, Cho‐Ming, Edward J. Randinitis, Artemios B. Vassos, et al.. (1997). Lack of Effect of Type II Diabetes on the Pharmacokinetics of Troglitazone in a Multiple‐Dose Study. The Journal of Clinical Pharmacology. 37(12). 1114–1120. 41 indexed citations
17.
Wei, Xiaoxiong, Cho‐Ming Loi, Eric J. Jarvi, & Robert E. Vestal. (1995). Relative potency of mexiletine, lidocaine, and tocainide as inhibitors of rat liver CYP1A1 activity.. Drug Metabolism and Disposition. 23(12). 1335–1338. 14 indexed citations
18.
Vestal, Robert E., Barry J. Cusack, Joseph J. Crowley, & Cho‐Ming Loi. (1993). Aging and the response to inhibition and induction of theophylline metabolism. Experimental Gerontology. 28(4-5). 421–433. 10 indexed citations
19.
Loi, Cho‐Ming, et al.. (1990). Hepatic Drug Metabolism and Aging. Clinical Pharmacokinetics. 19(5). 359–389. 152 indexed citations
20.
Loi, Cho‐Ming & Robert E. Vestal. (1988). Drug metabolism in the elderly. Pharmacology & Therapeutics. 36(1). 131–149. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Greg Slatter Breakdown of academic impact, for papers by David R. Jones Breakdown of academic impact, for papers by Geert Mannens Breakdown of academic impact, for papers by Hidetaka Kamimura Breakdown of academic impact, for papers by Satoru Asahi Breakdown of academic impact, for papers by Adrian J. Fretland Breakdown of academic impact, for papers by Heidi J. Einolf Breakdown of academic impact, for papers by S. Cholerton Breakdown of academic impact, for papers by Mats Hidestrand Breakdown of academic impact, for papers by Alvin Gomez
Rankless by CCL
2026